Nexavar does not impact Progen's operations?????
Q. Why is Nexavar mentioned as a competitor in Progen's annual report?
A. Because it is a competitor.
Q. Is Nexavar going to be marketed for resectable liver cancer?
A. YES
Q. IF PI-88 passes Phase III and gets FDA approval, is there going to be a market for it?
A. Maybe, but a much reduced one.
